Image: The global immunoassay instruments/analyzers market is expected to reach USD 23.3 billion by 2024 (Photo courtesy of Shutterstock).
The global immunoassay instruments/analyzers market was valued at USD 14.7 billion in 2015 and is expected to reach USD 23.3 billion by 2024, driven by the continuous introduction of advanced products, as well as growing clinical applications for investigation and diagnosis of various chronic and related infectious diseases.
These are the findings of Grand View Research, Inc. (San Francisco, CA, USA), a market research and consulting company.
Product-wise, the immunoassay instruments market is segmented into chemiluminescence immunoassay, immunofluorescence analyzers, radioimmunoassay, enzyme-linked immunoassay, and consumables. In 2015, the consumables segment was the largest revenue generating space with over a market share of 70%, led by the repeated purchase of consumables and portable point-of-care kits. Enzyme-linked Immunoassay (ELISA) accounted for the second largest market share after consumables due to high sensitivity and wide application in a number of diagnostic tests. However, the introduction of high throughput techniques and automation of screening processes is also fueling the demand for chemiluminescence assays.
Application-wise, the immunoassay instruments market is segmented into therapeutic drug monitoring, oncology, cardiology, endocrinology, infectious disease testing and autoimmune disease. The increasing prevalence of infectious diseases, like tuberculosis, cholera, and typhoid, and chronic conditions, such as cancer, autoimmune disorders, etc., which require early diagnosis, prevention, and treatment, is one of the key factors driving the demand for immunoassay analyzers and compact consumable products in the healthcare sector. Increasing cross-country migration, unhealthy sanitary habits, and drug resistance due to genetic mutations in viruses and bacteria, are resulting in rising incidences of infectious diseases across the world. The high prevalence of infectious diseases, coupled with government initiatives to limit hospital acquired infections, which has led to the adoption of diagnostic measures, resulted in the infectious disease testing segment commanding the largest market share among all applications in 2015.
Regarding region-wise performance, the constant introduction and adoption of automated as well as advanced techniques for laboratory instruments and analyzers in developed countries is driving the overall market growth. In 2015, North America captured the largest revenue share of around 37% of the global market, on the back of continuous research on treatment of infectious diseases and subsequent grants from government healthcare agencies. The growing geriatric population in India, China, and Japan has led to an increase in the prevalence of infectious diseases and various chronic conditions, thus promoting the utilization of immunoassays in the region. The market in Asia Pacific is also receiving a boost from major pharmaceutical players shifting their manufacturing facilities to the region, which offers affordable and skilled labor along with advanced manufacturing infrastructure.
Going forward, the expected CAGR of around 5% in the global immunoassay instruments market from 2016 to 2024 will be led by the consumables segment, which is likely to record the fastest growth with a CAGR of 5.5%, driven by the introduction of improved and user-friendly products such as portable kits and paper-based electrochemical devices. The chemiluminescence assays segment is also expected to record a significant growth rate over the forecast period. Asia Pacific is expected to witness the fastest growth with a CAGR of 7.0% from 2016 to 2024, aided further by the booming medical tourism industry in the region that is expected to fuel the demand for immunoassays in countries such as Japan, China, Malaysia, Thailand, and India.
Grand View Research